Dividend Overview
Dividend Yield
—
Dividend / Share
—
Alkermes plc
Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Alkermes plc, a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio.
Current Price
$37.48
-2.29%GoodMoat Value
$101.41
170.6% undervaluedProfile
Valuation (TTM)
Market Cap$6.25B
P/E40.90
EV—
P/B3.43
Shares Out166.65M
P/Sales4.00
Revenue$1.56B
EV/EBITDA26.47
Alkermes plc (ALKS) Dividends
Key Metrics
Market Cap
$6.25B
P/E Ratio
40.90
Forward P/E
—
EPS
$1.43
PEG Ratio
-0.11
Book Value
$10.92
Dividend Yield
—
Profit Margin
9.78%
ROE
8.39%
Dividend History
Dividend Safety
ALKS Dividend Analysis
Alkermes plc (ALKS) dividend analysis including yield, payout history, and sustainability metrics.
P/E ratio: 40.90. Profit margin: 9.78%. Free cash flow: $483.13M. This page shows Alkermes plc's dividend overview, key metrics, historical payout data, and dividend safety assessment to help income-focused investors evaluate the sustainability of dividend payments.
GoodMoat's dividend analyzer evaluates payout ratios, earnings coverage, and free cash flow coverage to determine how well supported Alkermes plc's dividend payments are. Use this analysis alongside the company's financial statements and quality score to make informed income-investing decisions.